AO-176, a highly differentiated humanized anti-CD47 antibody, exhibits single -agent and combination antitumor efficacy with chemotherapy and targeted antibodies

被引：1
|
作者：
Wilson, Casey [1 ]
Bouchlaka, Myriam [1 ]
Puro, Robyn [1 ]
Capoccia, Ben [1 ]
Hiebsch, Ronald [1 ]
Chakraborty, Prabir [1 ]
Donio, Michael [1 ]
Sung, Vicki [2 ]
Pereira, Daniel [1 ]
机构：
[1] Arch Oncol, St Louis, MO USA
[2] Arch Oncol, Brisbane, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-19-B100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B100
引用
收藏
页数：2
相关论文
共 17 条
  • [1] Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination
    Richards, John
    Bouchlaka, Myriam N.
    Puro, Robyn J.
    Capoccia, Ben J.
    Hiebsch, Ronald R.
    Donio, Michael J.
    Wilson, W. Casey
    Chakraborty, Prabir
    Sung, Victoria
    Pereira, Daniel S.
    BLOOD, 2019, 134
  • [2] AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics
    Wilson, William Casey
    Richards, John
    Puro, Robyn J.
    Andrejeva, Gabriela
    Capoccia, Ben J.
    Donio, Mike J.
    Hiebsch, Ronald R.
    Chakraborty, Prabir
    Sung, Victoria
    Pereira, Daniel S.
    BLOOD, 2020, 136
  • [3] A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.
    Burris, Howard A., III
    Spira, Alexander I.
    Taylor, Matthew H.
    Yeku, Oladapo O.
    Liu, Joyce F.
    Munster, Pamela N.
    Hamilton, Erika P.
    Thomas, Jacob Stephen
    Gatlin, Frances
    Penson, Richard T.
    Abrams, Thomas Adam
    Dhawan, Mallika Sachdev
    Walling, Jacqueline M.
    Frye, John W.
    Romanko, Kevin
    Sung, Victoria
    Brachmann, Carrie
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] AO-176, a highly differentiated clinical stage anti-CD47 antibody, is efficacious in pre-clinical models of lymphoma.
    Capoccia, Benjamin J.
    Donio, Michael J.
    Richards, John O.
    Hiebsch, Ronald R.
    Puro, Robyn J.
    Kashyap, Arun K.
    Pereira, Daniel S.
    CANCER RESEARCH, 2021, 81 (13)
  • [5] AO-176, a next-generation anti-CD47 antibody, induces immunogenic cell death
    Pereira, Daniel S.
    Capoccia, Benjamin J.
    Hiebsch, Ronald R.
    Donio, Michael J.
    Carter, Alun J.
    Puro, Robyn J.
    Wilson, W. Casey
    Manning, Pamela T.
    Carr, Robert W.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [6] AO-176, A HIGHLY DIFFERENTIATED CLINICAL STAGE ANTI-CD47 ANTIBODY, PREFERENTIALLY BINDS TUMOR VERSUS NORMAL CELL CD47 WHEN COMPLEXED TO β1 INTEGRIN
    Puro, Robyn
    Chakraborty, Prabir
    Richards, John
    Hiebsch, Ronald
    Donio, Michael
    Wilson, W. Casey
    Capoccia, Benjamin
    Brachmann, Carrie
    Sung, Vicki
    Kashyap, Arun
    Pereira, Daniel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A128 - A129
  • [7] Development of AO-176, a next generation humanized anti-CD47 antibody with novel anti-cancer properties and negligible binding to red blood cells
    Bouchlaka, M. N.
    Puro, R.
    Capoccia, B.
    Donio, M.
    Hiebsch, R.
    Carter, A. J.
    Crowley, K. S.
    Wilson, W. C.
    Chakraborty, P.
    Manning, P. T.
    Karr, R.
    Sung, V.
    Pereira, D. S.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E76 - E76
  • [8] Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
    Puro, Robyn J.
    Bouchlaka, Myriam N.
    Hiebsch, Ronald R.
    Capoccia, Benjamin J.
    Donio, Michael J.
    Manning, Pamela T.
    Frazier, William A.
    Karr, Robert W.
    Pereira, Daniel S.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (03) : 835 - 846
  • [9] AO-176, a Differentiated Clinical-Stage Anti-CD47 Antibody, Demonstrates Potent Anti-Tumor Activity across Multiple Preclinical Models of B Cell Neoplasms
    Wilson, William Casey
    Richards, John O.
    Andrejeva, Gabriela
    Capoccia, Benjamin J.
    Puro, Robyn J.
    Donio, Mike J.
    Hiebsch, Ronald R.
    Kashyap, Arun K.
    Pereira, Daniel S.
    BLOOD, 2021, 138
  • [10] The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL).
    Lock, Richard B.
    Evans, Kathryn
    El-Zein, Narimanne
    Earley, Eric J.
    Erickson, Stephen W.
    Teicher, Beverly A.
    Sung, Victoria
    Smith, Malcolm A.
    CANCER RESEARCH, 2021, 81 (13)
12